Intrinsic Medicine

Intrinsic Medicine is a patient solutions-focused biotechnology company with a platform and culture built to efficiently and ethically bring transformative new medicines to people living with gut-brain axis (GBA) disorders.

Intrinsic Medicine focuses on the creation of Human identical Milk Oligosaccharides (HiMO) drugs derived from foundational human biology to treat a spectrum of human diseases. These HiMO drugs offer a favorable safety profile and possess multiple synergistic modes of action, particularly suited for addressing complex diseases like Gut Immune Microbiome Brain Axis Disorders (GIMBADs). 

Supported by investors such as SOSV, Atomikz, and WRF Capital, Intrinsic Medicine is poised to revolutionize the treatment landscape for complex diseases with its HiMO drug platform.

Intrinsic Medicine, founded in 2022 by Alexander Martinez and Jason Ferrone, has swiftly emerged as a pioneering force in the healthcare industry, leveraging human milk biology to transform the treatment landscape for Gut-Brain Axis (GBA) and inflammatory disorders. The company's journey has been marked by strategic partnerships, significant funding rounds, and groundbreaking developments in drug discovery. In September 2022, Intrinsic Medicine raised an undisclosed amount in convertible notes from IndieBio and SOSV, followed by another undisclosed seed funding round in October 2019 from the same investors. These investments facilitated the advancement of the company's pipeline, particularly its lead drug candidate, OM002 (2’-fucosyllactose, or 2’FL), aimed at treating constipation-dominant irritable bowel syndrome (IBS-C). In June 2021, Intrinsic Medicine secured $113 million in Series A funding, led by Define Ventures, with participation from Link Ventures and others. This substantial investment highlighted the industry's confidence in Intrinsic's innovative approach and potential to revolutionise healthcare. Additionally, the company established a medical advisory board comprising esteemed professionals from various medical disciplines to guide its acquisition and innovation strategies.

Amidst its growth trajectory, Intrinsic Medicine entered a merger agreement with Phoenix Biotech Acquisition Corp. in November 2022, with plans to list on Nasdaq under the ticker symbol "INRX." However, this agreement was mutually terminated due to prevailing market conditions, allowing Intrinsic to maintain its focus on advancing transformative therapeutics. In the first half of 2023, Intrinsic Medicine plans to initiate Phase 2 clinical trials for OM002 in Australia, targeting over 400 patients with IBS-C. The company's robust pipeline includes OM001 (3'SL or sialyllactose) and OM003 (6'SL), being advanced for various indications, including rheumatoid arthritis, juvenile idiopathic arthritis, atopic dermatitis, and autism spectrum disorder. Intrinsic Medicine's relentless pursuit of innovative solutions, coupled with its strategic alliances and visionary leadership, positions it at the forefront of therapeutic innovation, poised to redefine the standard of care for complex diseases affecting millions worldwide.

The mission of Intrinsic Medicine is to pioneer transformative therapies for complex human diseases through the development of HiMO drugs, leveraging foundational human biology. With a focus on addressing Gut Immune Microbiome Brain Axis Disorders (GIMBADs) and other multifaceted conditions, its goal is to offer safe, effective, and innovative treatment options that harness the synergistic modes of action inherent in HiMO drugs. 

By advancing scientific understanding and accelerating the translation of research into clinical practice, Intrinsic Medicine aims to improve patient outcomes, reduce healthcare burdens, and ultimately enhance the quality of life for individuals affected by these challenging diseases.

Intrinsic Medicine envisions a future where the complexities of Gut Immune Microbiome Brain Axis Disorders (GIMBADs) and other intricate human diseases are effectively addressed through groundbreaking HiMO drug therapies. Its vision is to redefine the treatment landscape by harnessing the synergistic potential of HiMO drugs, derived from foundational human biology, to provide safe, personalised, and transformative solutions for patients worldwide. 

By pushing the boundaries of scientific discovery and therapeutic innovation, Intrinsic Medicine aspires to pioneer a new era of healthcare where individuals have access to targeted, holistic treatments that address the underlying mechanisms of disease, leading to improved outcomes, enhanced well-being, and a healthier global population.

Intrinsic Medicine offers transformative products and services centered around Human Identical Milk Oligosaccharides (HiMOs), derived from foundational human biology and inspired by the science of human milk. 

HiMOs are synthetic biology-produced prebiotic drugs that closely mimic the function of naturally occurring Human Milk Oligosaccharides (HMOs), offering a profound safety profile and potent human bioactivity. The company's approach to drug development focuses on addressing complex human diseases, particularly Gut Immune Microbiome Brain Axis Disorders (GIMBADs), with HiMO drugs exhibiting multiple synergistic modes of action. 

Intrinsic Medicine's platform provides a distinct advantage over traditional drug development pathways, offering rapid translation from disease identification to clinical trials, potentially saving significant research costs and development timelines. With a commitment to unlocking nature's library of oligosaccharides and advancing therapeutic innovation, Intrinsic Medicine aims to revolutionise the treatment landscape, improve patient outcomes, and enhance global healthcare accessibility. Supported by investors such as SOSV, Atomikz, and WRF Capital, Intrinsic Medicine is poised to lead the way in transforming healthcare through innovative HiMO drug therapies.